CERITINIB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER

被引：3

作者：

Landi, L. ^{[1
]}

Cappuzzo, F. ^{[1
]}

机构：

[1] Inst Toscano Tumori, Dept Med Oncol, I-57100 Livorno, Italy

来源：

DRUGS OF TODAY | 2014年 / 50卷 / 07期

关键词：

Non-small cell lung cancer; ALK-positive NSCLC; Antitumor activity; Ceritinib; LDK-378; ANAPLASTIC LYMPHOMA KINASE; EML4-ALK FUSION GENE; RECEPTOR GENE; ALK; GEFITINIB; THERAPY; SENSITIVITY; CRIZOTINIB; MUTATIONS; TUMORS;

D O I：

10.1358/dot.2014.50.7.2133568

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Non-small cell lung cancer (NSCLC) represents the paradigm of personalized treatment in human cancer. Several oncogenic alterations with druggable potential have been identified, with ALK rearrangements representing one of the newest and most appealing. Crizotinib is now recognized as the standard of care in chemotherapy-pretreated ALK-positive NSCLC due to the positive results of a recently published trial. Unfortunately, no patient exposed to crizotinib can be cured, and after a median time of 1 year, resistance inevitably occurs. Overcoming resistance is the major challenge in clinical oncology and many molecules are currently under evaluation, including ceritinib (LDK-378). Ceritinib is an oral, potent, second-generation ALK inhibitor recently approved by the U.S. Food and Drug Administration. Preclinical data showed impressive antitumor activity against crizotinib-resistant clones, and based on available data, ceritinib could represent a suitable option in crizotinib-resistant NSCLC.

引用

页码：465 / 473

页数：9

共 25 条

[1] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

[2] Treating ALK-positive lung cancer-early successes and future challenges [J].

Camidge, D. Ross ;

Doebele, Robert C. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (05) :268-277

[3] HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer [J].

Cappuzzo, F ;

Bemis, L ;

Varella-Garcia, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2619-2621

[4] Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients [J].

Cappuzzo, F ;

Varella-Garcia, M ;

Shigematsu, H ;

Domenichini, I ;

Bartolini, S ;

Ceresoli, GL ;

Rossi, E ;

Ludovini, V ;

Gregorc, V ;

Toschi, L ;

Franklin, WA ;

Crino, L ;

Gazdar, AF ;

Bunn, RA ;

Hirsch, FR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5007-5018

[5] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[6] The anaplastic lymphoma kinase in the pathogenesis of cancer [J].

Chiarle, Roberto ;

Voena, Claudia ;

Ambrogio, Chiara ;

Piva, Roberto ;

Inghirami, Giorgio .

NATURE REVIEWS CANCER, 2008, 8 (01) :11-23

[7] Isolated central nervous system progression on Crizotinib An Achilles heel of non-small cell lung cancer with EML4-ALK translocation? [J].

Chun, Stephen G. ;

Choe, Kevin S. ;

Iyengar, Puneeth ;

Yordy, John S. ;

Timmerman, Robert D. .

CANCER BIOLOGY & THERAPY, 2012, 13 (14) :1376-1383

[8] Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers [J].

Katayama, Ryohei ;

Shaw, Alice T. ;

Khan, Tahsin M. ;

Mino-Kenudson, Mari ;

Solomon, Benjamin J. ;

Halmos, Balazs ;

Jessop, Nicholas A. ;

Wain, John C. ;

Yeo, Alan Tien ;

Benes, Cyril ;

Drew, Lisa ;

Saeh, Jamal Carlos ;

Crosby, Katherine ;

Sequist, Lecia V. ;

Iafrate, A. John ;

Engelman, Jeffrey A. .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (120)

[9] EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer [J].

Koivunen, Jussi P. ;

Mermel, Craig ;

Zejnullahu, Kreshnik ;

Murphy, Carly ;

Lifshits, Eugene ;

Holmes, Alison J. ;

Choi, Hwan Geun ;

Kim, Jhingook ;

Chiang, Derek ;

Thomas, Roman ;

Lee, Jinseon ;

Richards, William G. ;

Sugarbaker, David J. ;

Ducko, Christopher ;

Lindeman, Neal ;

Marcoux, J. Paul ;

Engelman, Jeffrey A. ;

Gray, Nathanael S. ;

Lee, Charles ;

Meyerson, Matthew ;

Janne, Pasi A. .

CLINICAL CANCER RESEARCH, 2008, 14 (13) :4275-4283

[10] Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer [J].

Kwak, Eunice L. ;

Bang, Yung-Jue ;

Camidge, D. Ross ;

Shaw, Alice T. ;

Solomon, Benjamin ;

Maki, Robert G. ;

Ou, Sai-Hong I. ;

Dezube, Bruce J. ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Varella-Garcia, Marileila ;

Kim, Woo-Ho ;

Lynch, Thomas J. ;

Fidias, Panos ;

Stubbs, Hannah ;

Engelman, Jeffrey A. ;

Sequist, Lecia V. ;

Tan, WeiWei ;

Gandhi, Leena ;

Mino-Kenudson, Mari ;

Wei, Greg C. ;

Shreeve, S. Martin ;

Ratain, Mark J. ;

Settleman, Jeffrey ;

Christensen, James G. ;

Haber, Daniel A. ;

Wilner, Keith ;

Salgia, Ravi ;

Shapiro, Geoffrey I. ;

Clark, Jeffrey W. ;

Iafrate, A. John .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1693-1703

← 1 2 3 →